Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 6 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1648     ISSN: 1756-7874

Section: Technology Access



Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details